Core Viewpoint - Shenzhen Core Medical Technology Co., Ltd. has successfully had its IPO application accepted by the Shanghai Stock Exchange, marking it as the first innovative medical device company to be accepted under the new fifth set of listing standards for the Sci-Tech Innovation Board [1] Company Summary - Core Medical has received investments from multiple seasoned professional institutional investors, including Zhuhai Hillhouse Private Equity Fund Management Co., Ltd. and Shanghai Zhengxin Valley Investment Management Co., Ltd. [1] - This acceptance follows the case of Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd., making Core Medical the second company to recognize seasoned professional institutional investors in its Sci-Tech Innovation Board application [1] Industry Summary - The acceptance of Core Medical's IPO application is seen as a practical implementation of the "Sci-Tech-Capital" dual circulation in the innovative medical device sector [1] - It highlights the clear direction of the Sci-Tech Innovation Board in providing essential capital market support for high-quality technology enterprises that have significant R&D investments and long profit cycles [1]

Core Viewpoint - Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd. (Tainuo Maibo) has become the first company to have its IPO application accepted under the new fifth set of listing standards for the Sci-Tech Innovation Board, marking a significant step in the implementation of the "1+6" new policy by the China Securities Regulatory Commission [1][2] Company Overview - Tainuo Maibo was established in 2015 and is an innovative biopharmaceutical company [2] - The company's core product, Staidotamab Injection (New Taimo®), is the world's first recombinant monoclonal antibody drug against tetanus toxin, approved for market in February 2025 [2] - Tainuo Maibo has invested over 1.1 billion yuan in research and development over the past three years [2] Product Development - The company has developed several core technology platforms, including the HitmAb® high-throughput fully human monoclonal antibody research platform and the efficient antibody expression CHO-GS cell platform [2] - The core product currently under development, TNM001, is a long-acting monoclonal antibody for the prevention of RSV in healthy and high-risk infants, which is in Phase III clinical trials [2] - The company is also exploring other therapeutic areas, including pain relief (TNM009), prevention of chickenpox and shingles (TNM005), and prevention of human cytomegalovirus (TNM006) [2]